RxDoctor Payments Data

Hilma Campbell

Psychiatric/Mental Health · Brooklyn, NYNPI 1245760503

Payments from drug & device makers

$2,103in general payments, 2019–2025

Across 43 payments — averaging $48.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$739
  • Alkermes, Inc.$398
  • Teva Pharmaceuticals USA, Inc.$334
  • Vanda Pharmaceuticals Inc.$166
  • AbbVie$143
  • E.r. Squibb & Sons, L.L.C.$125
  • plus $197 from 2 others

What the payments were for

  • Food & beverage$2,103100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,103 in reported general payments places this provider in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$13,747
Medicare patients
15
Services billed
176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl20$32,085
Abilify MaintenaAripiprazole11$32,038
RexultiBrexpiprazole18$24,454
LatudaLurasidone Hcl11$14,787
Fluvoxamine Maleate ErFluvoxamine Maleate12$8,245
Fluphenazine Hcl49$4,098
Aripiprazole144$3,070
Fluphenazine Decanoate25$1,829
Clonazepam196$1,496
Haloperidol63$1,379
Haloperidol Decanoate42$1,315
Lamotrigine ErLamotrigine11$1,293
Clomipramine Hcl12$1,097
Buspirone Hcl85$962
Quetiapine Fumarate105$956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$75$56,49229 claims
AbbVieVraylar$143$32,08520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →